24 August 2020>: Lab/In Vitro Research
Olmutinib Reverses Doxorubicin Resistance in ETS1-Overexpressing Leukemia Cells
Jiansheng Zhong 1ABE* , Jinli Zhang 2AB , Xiaoyang Yu 3BF , Xing Zhang 1CD , Linping Dian 1CDDOI: 10.12659/MSM.924922
Med Sci Monit 2020; 26:e924922
Table 1 Effect of olmutinib on enhancement of doxorubicin.
Compound | IC50 (μM) (fold-reversal) | |||
---|---|---|---|---|
K562 Oe-NC | K562 Oe-ETS1 | K562/ADR Oe-NC | K562/ADR Oe-ETS1 | |
Dox | 0.143±0.008 (1.00) | 0.197±0.009 (1.00) | 0.202±0.009 (1.00) | 2.432±0.131 (1.00)*** |
+Olm 0.25 μM | 0.136±0.018 (1.04) | 0.183±0.009 (1.07) | 0.184±0.01 (1.11) | 1.331±0.123 (1.71)*** |
+Olm 0.5 μM | 0.113±0.016 (1.22) | 0.168±0.097 (1.18) | 0.153±0.031 (1.21) | 0.501±0.107 (4.66)*** |
+Olm 1 μM | 0.061±0.009 (1.84) | 0.114±0.024 (1.73) | 0.109±0.063 (1.42) | 0.233±0.054 (10.08)*** |
The fold-reversal of MDR (values given in parentheses) was calculate as described in Material and Methods. Data are shown as the mean±standard deviation (SD) of 3 independent experiments. *** |